US09061H3075 - Common Stock
BIOMERICA INC
NASDAQ:BMRA (9/18/2024, 4:00:16 PM)
0.307
-0.02 (-6.69%)
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 62 full-time employees. The firm develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The company is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The firm's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Company’s two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.
BIOMERICA INC
17571 Von Karman Avenue
Irvine CALIFORNIA 92614
P: 19493792875
CEO: Zackary S. Irani
Employees: 62
Website: https://biomerica.com/
Unusual volume stocks are being observed in Thursday's session.
- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second...
Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger GrowthSignificant Cost Savings Plan...
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!
inFoods® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home ...
IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, today announced the initiation of a pilot program for its inFoods® IBS product with a large 1,100-member physician group. This pilot launch will commence in June 2024.
Here you can normally see the latest stock twits on BMRA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: